Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same

A compound of formula (I), or a pharmaceutically acceptable salt or a prodrug thereof:

• wherein,
• ring A is thiophene;
• and
• ring B is benzene, 5 to 10-membered heterocycloalkyl, or 5 to 13-membered heteroaryl, in which said ring A and ring B are each independently optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, mercapto, cyano, carboxy, nitro, guanidino, ureido, amino, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C1-7 alkoxy-C1-7 alkyl, C1-7 alkoxy, C1-7 alkoxy-C1-7 alkoxy, C2-7 alkenyloxy, C2-7 alkynyloxy, 5 to 10-membered heterocycloalkyloxy, C3-10 cycloalkyl, C5-10 cycloalkenyl, C3-10 cycloalkyloxy, phenyl-C1-7 alkoxy, mono- or di-C1-7 alkylamino, aminocarbonyl, C2-8 acylamino, C2-8 acyl, C1-7 alkoxycarbonyl, mono- or di-C1-7 alkylcarbamoyl, C1-7 alkylsulfonylamino, phenylsulfonylamino, C1-7 alkylsulfanyl, C1-7 alkylsulfinyl, C1-7 alkylsulfonyl, C6-14 arylsulfanyl, C6-14 arylsulfonyl, C6-14 aryl, C7-15 aroyl, 5 to 13-membered heteroaryl, 6 to 14-membered heteroaroyl, C7-15 aroyloxy, C2-8 acyloxy, 6 to 14-membered heteroaroyloxy, or 5 to 10-membered heterocycloalkyl,
• in which
• said alkyl, alkenyl, alkynyl, alkoxy, or acyl is optionally substituted with a substituent selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, and mercapto;
• said cycloalkyl, cycloalkenyl, aryl, aroyl, heteroaryl, heteroaroyl, or heterocycloalkyl is optionally substituted with a substituent selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C1-4 alkyl, and C1-4 alkoxy;
• and
• said heterocycloalkyl, heteroaryl, and heteroaroyl each independently contains at least one heteroatom selected from the group consisting of N, O and S.